Wolfgang Hoffmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wolfgang Hoffmann has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Peter T. Soboslay
Affiliation University Clinics Tübingen, Institute for Tropical Medicine, Eberhard-Karls University, Tübingen, Germany
2 shared publications Alexander Staudt
Department of Cardiology, Ernst-Moritz-Arndt University, Greifswald, Germany
1 shared publication- Andrea Kreidenweiss
Institute of Tropical Medicine, University of Tübingen, Germany
1 shared publication - Anna-Maria Rolle
Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Germany
1 shared publication Astrid Hummel
Department of Cardiology, Ernst-Moritz-Arndt University, Greifswald, Germany
1 shared publicationB. Bültmann
Institut für Pathologie, Universität Tübingen
1 shared publication
Latest Publications
- Open Access
- 24 June 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (6) , e0009511
Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
Background: Schistosomiasis is highly prevalent in Africa. Praziquantel is effective against adult schistosomes but leaves prepatent stages unaffected—which is a limit to patient management and elimination. Given the large-scale use of praziquantel, development of drug resistance by Schistosoma is feared. Antimalarials are promising drugs for alternative treatment strategies of Schistosoma infections. Development of drugs with activity against both malaria and schistosomiasis is particularly appealing as schistosome infections often occur concomitantly with malaria parasites in sub-Saharan Africa. Therefore, antiplasmodial compounds were progressively tested against Schistosoma in vitro, in mice, and in a clinical study. Results: Amongst 16 drugs and 1 control tested, pyronaridine, methylene blue and 5 other antimalarials were highly active in vitro against larval stage schistosomula with a 50% inhibitory concentration below 10 μM. Both drugs were lethal to ex vivo adult worms tested at 30 μM with methylene blue also active at 10 μM. Pyronaridine treatment of mice infected with S. mansoni at the prepatent stage reduced worm burden by 82% and cured 7 out of 12 animals, however in mice adult stages remained viable. In contrast, methylene blue inhibited adult worms by 60% but cure was not achieved. In an observational pilot trial in Gabon in children, the antimalarial drug combination pyronaridine-artesunate (Pyramax) reduced S. haematobium egg excretion from 10/10 ml urine to 0/10 ml urine, and 3 out of 4 children were cured. Conclusion: Pyronaridine and methylene blue warrant further investigation as candidates for schistosomiasis treatment. Both compounds are approved for human use and evidence for their potential as antischistosomal compounds can be obtained directly from clinical testing. Particularly, pyronaridine-artesunate, already available as an antimalarial drug, calls for further clinical evaluation. Trial registration: ClinicalTrials.gov Identifier NCT03201770.
- 24 June 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (6) , e0009511
Open AccessEvidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
Background: Schistosomiasis is highly prevalent in Africa. Praziquantel is effective against adult schistosomes but leaves prepatent stages unaffected—which is a limit to patient management and elimination. Given the large-scale use of praziquantel, development of drug resistance by Schistosoma is feared. Antimalarials are promising drugs for alternative treatment strategies of Schistosoma infections. Development of drugs with activity against both malaria and schistosomiasis is particularly appealing as schistosome infections often occur concomitantly with malaria parasites in sub-Saharan Africa. Therefore, antiplasmodial compounds were progressively tested against Schistosoma in vitro, in mice, and in a clinical study. Results: Amongst 16 drugs and 1 control tested, pyronaridine, methylene blue and 5 other antimalarials were highly active in vitro against larval stage schistosomula with a 50% inhibitory concentration below 10 μM. Both drugs were lethal to ex vivo adult worms tested at 30 μM with methylene blue also active at 10 μM. Pyronaridine treatment of mice infected with S. mansoni at the prepatent stage reduced worm burden by 82% and cured 7 out of 12 animals, however in mice adult stages remained viable. In contrast, methylene blue inhibited adult worms by 60% but cure was not achieved. In an observational pilot trial in Gabon in children, the antimalarial drug combination pyronaridine-artesunate (Pyramax) reduced S. haematobium egg excretion from 10/10 ml urine to 0/10 ml urine, and 3 out of 4 children were cured. Conclusion: Pyronaridine and methylene blue warrant further investigation as candidates for schistosomiasis treatment. Both compounds are approved for human use and evidence for their potential as antischistosomal compounds can be obtained directly from clinical testing. Particularly, pyronaridine-artesunate, already available as an antimalarial drug, calls for further clinical evaluation. Trial registration: ClinicalTrials.gov Identifier NCT03201770.
- 6 January 2015
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 17 (4) , 512-520
Evaluation of the Metabolic Activity of Echinococcus multilocularis in Rodents Using Positron Emission Tomography Tracers
2-Deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) has been used as a standard clinical positron emission tomography (PET) tracer for the follow-up of the rare but life-threatening parasitic disease alveolar echinococcosis (AE). Given that the disease is endemic in many countries in the northern hemisphere and the diagnosis is still challenging, the aim of our study was to evaluate further clinically relevant PET tracers as possible diagnostic tools for AE in vitro and in vivo. Various clinically used PET tracers were evaluated in vitro and assessed in an in vivo AE animal model based on PET/magnetic resonance (MR) measurements. In vitro binding assays displayed high uptake of [(18)F]FDG in a cell suspension of E. multilocularis tissue, whereas 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) and [(11)C]choline were found to be taken up strongly by E. multilocularis vesicles. [(18)F]FDG and [(18)F]FLT displayed an elevated uptake in vivo, which appeared as several foci throughout the parasite tissue as opposed to [(18)F]fluoro-azomycinarabinofuranoside ([(18)F]FAZA) and [(11)C]choline. Our data clearly demonstrate that the clinically applied PET tracer [(18)F]FDG is useful for the diagnosis and disease staging of AE but also has drawbacks in the assessment of currently inactive or metabolically weak parasitic lesions. The different tested PET tracers do not show the potential for the replacement or supplementation of current diagnostic strategies. Hence, there is still the need for novel diagnostic tools.
- 6 January 2015
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 17 (4) , 512-520
Evaluation of the Metabolic Activity of Echinococcus multilocularis in Rodents Using Positron Emission Tomography Tracers
2-Deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) has been used as a standard clinical positron emission tomography (PET) tracer for the follow-up of the rare but life-threatening parasitic disease alveolar echinococcosis (AE). Given that the disease is endemic in many countries in the northern hemisphere and the diagnosis is still challenging, the aim of our study was to evaluate further clinically relevant PET tracers as possible diagnostic tools for AE in vitro and in vivo. Various clinically used PET tracers were evaluated in vitro and assessed in an in vivo AE animal model based on PET/magnetic resonance (MR) measurements. In vitro binding assays displayed high uptake of [(18)F]FDG in a cell suspension of E. multilocularis tissue, whereas 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) and [(11)C]choline were found to be taken up strongly by E. multilocularis vesicles. [(18)F]FDG and [(18)F]FLT displayed an elevated uptake in vivo, which appeared as several foci throughout the parasite tissue as opposed to [(18)F]fluoro-azomycinarabinofuranoside ([(18)F]FAZA) and [(11)C]choline. Our data clearly demonstrate that the clinically applied PET tracer [(18)F]FDG is useful for the diagnosis and disease staging of AE but also has drawbacks in the assessment of currently inactive or metabolically weak parasitic lesions. The different tested PET tracers do not show the potential for the replacement or supplementation of current diagnostic strategies. Hence, there is still the need for novel diagnostic tools.
- 1 September 2010
- Published by Elsevier in American Heart Journal
- Vol. 160 (3) , 552-563
Comparison of rotational with conventional coronary angiography
- 1 September 2010
- Published by Elsevier in American Heart Journal
- Vol. 160 (3) , 552-563
Comparison of rotational with conventional coronary angiography
- 1 January 2006
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 19 (6) , 371-379
Regulation of Nitric Oxide Synthesis in Wounds by IFN-γ Depends on TNF-α
Macrophage-derived nitric oxide is a critical mediator in wound healing. Its regulation in vivo, however, remains unclear. We hypothesized that interferon (IFN)-γ plays an important role in the regulation of nitric oxide in wounds. Groups of 12 male IFN-γ -knockout mice and wild-type controls underwent dorsal skin incision and polyvinyl alcohol sponges were inserted subcutaneously. Mice were sacrificed 10 days later to determine wound breaking strength and reparative collagen deposition. Synthesis of nitric oxide (NO), tumor necrosis factor (TNF)-α, and IFN-γ was measured in the wound. Wound-derived macrophages were tested for NO synthesis in the presence or absence of IFN-γ, TNF-α, and anti-TNF-α antibody. In a separate experiment, IFN-γ -knockout mice and wild-type controls were treated with molsidomine, a nitric oxide donor. It was found that wound collagen deposition and wound breaking strength were impaired in IFN-γ-knockout mice (p <. 05). Impaired healing was reflected in diminished synthesis of TNF-α and NO in wounds (p <. 05). In vivo treatment with molsidomine reversed impaired healing in IFN-γ-deficient mice. Ex vivo, addition of IFN-γ stimulated the synthesis of TNF-α and NO in wound-derived macrophages. IFN-γ -induced NO synthesis by wound-derived macrophages was abolished by anti-TNF-α-antibody-treatment, which could be fully reversed by exogenous TNF-α. Thus we conclude that IFN-γ-deficiency impairs wound healing and diminishes NO synthesis in wound-derived macrophages. The stimulatory effect of IFN-γ on macrophage NO production depends on endogenous TNF-α synthesis.
- 1 January 2006
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 19 (6) , 371-379
Regulation of Nitric Oxide Synthesis in Wounds by IFN-γ Depends on TNF-α
Macrophage-derived nitric oxide is a critical mediator in wound healing. Its regulation in vivo, however, remains unclear. We hypothesized that interferon (IFN)-γ plays an important role in the regulation of nitric oxide in wounds. Groups of 12 male IFN-γ -knockout mice and wild-type controls underwent dorsal skin incision and polyvinyl alcohol sponges were inserted subcutaneously. Mice were sacrificed 10 days later to determine wound breaking strength and reparative collagen deposition. Synthesis of nitric oxide (NO), tumor necrosis factor (TNF)-α, and IFN-γ was measured in the wound. Wound-derived macrophages were tested for NO synthesis in the presence or absence of IFN-γ, TNF-α, and anti-TNF-α antibody. In a separate experiment, IFN-γ -knockout mice and wild-type controls were treated with molsidomine, a nitric oxide donor. It was found that wound collagen deposition and wound breaking strength were impaired in IFN-γ-knockout mice (p <. 05). Impaired healing was reflected in diminished synthesis of TNF-α and NO in wounds (p <. 05). In vivo treatment with molsidomine reversed impaired healing in IFN-γ-deficient mice. Ex vivo, addition of IFN-γ stimulated the synthesis of TNF-α and NO in wound-derived macrophages. IFN-γ -induced NO synthesis by wound-derived macrophages was abolished by anti-TNF-α-antibody-treatment, which could be fully reversed by exogenous TNF-α. Thus we conclude that IFN-γ-deficiency impairs wound healing and diminishes NO synthesis in wound-derived macrophages. The stimulatory effect of IFN-γ on macrophage NO production depends on endogenous TNF-α synthesis.
- 1 January 1996
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 19 (6) , 508-511
13-Cis Retinoic Acid, Interferon-alpha and Concomittant Irradiation in a Patient with Non-Small-Cell Lung Cancer – Description of Toxicity and Response
Background: Interferon-alpha (IFN-alpha) and retinoic acid have been found to be active agents in the treatment of squamous-cell carcinomas. Recent experimental and clinical studies indicate an improvement of treatment results, if this agents are combined with irradiation. Material and Method: We report about a 53-year-old patient presenting with an advanced non-small-cell lung cancer. Systemical treatment with IFN-alpha and 13-cis retinoic acid was performed concurrently with radiotherapy. The patient’s follow-up, response and toxicity of this therapeutic regimen were evaluated. Result and Conclusions: The combination of IFN-alpha/retinoic acid with irradiation seems to be effective in the management of advanced non-small-cell carcinomas of the lung. However, in rare cases combined treatment with IFN-alpha and radiotherapy may be associated with increased side effects, especially radiation pneumonitis.
- 1 January 1996
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 19 (6) , 508-511
13-Cis Retinoic Acid, Interferon-alpha and Concomittant Irradiation in a Patient with Non-Small-Cell Lung Cancer – Description of Toxicity and Response
Background: Interferon-alpha (IFN-alpha) and retinoic acid have been found to be active agents in the treatment of squamous-cell carcinomas. Recent experimental and clinical studies indicate an improvement of treatment results, if this agents are combined with irradiation. Material and Method: We report about a 53-year-old patient presenting with an advanced non-small-cell lung cancer. Systemical treatment with IFN-alpha and 13-cis retinoic acid was performed concurrently with radiotherapy. The patient’s follow-up, response and toxicity of this therapeutic regimen were evaluated. Result and Conclusions: The combination of IFN-alpha/retinoic acid with irradiation seems to be effective in the management of advanced non-small-cell carcinomas of the lung. However, in rare cases combined treatment with IFN-alpha and radiotherapy may be associated with increased side effects, especially radiation pneumonitis.
- 1 May 1992
- Published by Elsevier in Parasitology Today
- Vol. 8 (5) , 152-153
Ivermectin-facilitated immunity
- 1 May 1992
- Published by Elsevier in Parasitology Today
- Vol. 8 (5) , 152-153
Ivermectin-facilitated immunity